Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease MESHD 2019: A Systematic Review and Meta-Analysis

    Authors: Vignesh Chidambaram; Nyan Lynn Tun; Waqas Haque; Marie Gilbert Majella; Ranjith Kumar Sivakumar; Amudha Kumar; Angela Ting-Wei Hsu; Izza Ishak; Aqsha Nur; Samuel Ayeh; Emmanuella Salia; Ahsan Zil-E-Ali; Muhammad Saeed; Ayu Sarena; Bhavna Seth; Muzzammil Ahmadzada; Eman Haque; Pranita Neupane; Kuang-Heng Wang; Tzu-Miao Pu; Syed Ali; Muhammad Arshad; Lin Wang; Sheriza Baksh; Petros Karakousis; Panagis Galiatsatos

    doi:10.1101/2020.08.07.20166868 Date: 2020-08-13 Source: medRxiv

    Background: Understanding the factors associated with disease severity and mortality in Coronavirus disease MESHD (COVID19) is imperative to effectively triage patients. We performed a systematic review to determine the demographic, clinical, laboratory and radiological factors associated with severity and mortality in COVID-19. Methods: We searched PubMed, Embase and WHO database for English language articles from inception until May 8, 2020. We included Observational studies with direct comparison of clinical characteristics between a) patients who died and those who survived or b) patients with severe disease and those without severe disease. Data extraction and quality assessment were performed by two authors independently. Results: Among 15680 articles from the literature search, 109 articles were included in the analysis. The risk of mortality was higher in patients with increasing age TRANS, male TRANS gender TRANS (RR 1.45; 95%CI 1.23,1.71), dyspnea HP dyspnea MESHD (RR 2.55; 95%CI 1.88,2.46), diabetes MESHD (RR 1.59; 95%CI 1.41,1.78), hypertension HP hypertension MESHD (RR 1.90; 95%CI 1.69,2.15). Congestive heart failure HP Congestive heart failure MESHD (OR 4.76; 95%CI 1.34,16.97), hilar lymphadenopathy HP lymphadenopathy MESHD (OR 8.34; 95%CI 2.57,27.08), bilateral lung involvement (OR 4.86; 95%CI 3.19,7.39) and reticular pattern (OR 5.54; 95%CI 1.24,24.67) were associated with severe disease. Clinically relevant cut-offs for leukocytosis HP leukocytosis MESHD(>10.0 x109/L), lymphopenia HP lymphopenia MESHD(< 1.1 x109/L), elevated C-reactive protein(>100mg/L), LDH(>250U/L) and D-dimer(>1mg/L) had higher odds of severe disease and greater risk of mortality. Conclusion: Knowledge of the factors associated of disease severity and mortality identified in our study may assist in clinical decision-making and critical-care resource allocation for patients with COVID-19.

    Analysis of the Primary Presenting Symptoms and Hematological Findings of COVID-19 Patients in Bangladesh

    Authors: Abu Taiub Mohammed Mohiuddin Chowdhury; Md Rezaul Karim; H.M. Hamidullah Mehedi; Mohammad Shahbaz; Md Wazed Chowdhury; Guo Dan; Shuixiang He

    id:10.20944/preprints202006.0275.v1 Date: 2020-06-21 Source: Preprints.org

    Objective: SARS-Cov-2 infection MESHD or COVID-19 is a global pandemic. From the time of identification to till, multiple clinical symptoms and parameters have been identified by the researchers of various countries and regions regarding the diagnosis and presentations of COVID-19 disease. In this manuscript, we investigated the primary symptoms and basic hematological presentations of SARS-CoV-2 infection MESHD among the Bangladeshi patients. Methodology: We have collected the disease history of mild to moderate degree of COVID-19 patients; hematological MESHD and biochemical on admission reports of moderate degree COVID-19 patients. All of them were tested positive for SARS-CoV-2 by RT-PCR in different institutes in Bangladesh. Results: According to this study though COVID-19 patients in Bangladesh commonly presented with fever HP fever MESHD, cough HP cough MESHD, fatigue HP fatigue MESHD, shortness of breath MESHD, and sore throat, but symptoms like myalgia HP myalgia MESHD, diarrhea HP diarrhea MESHD, skin rash HP skin rash MESHD, headache HP headache MESHD, Abdominal pain HP Abdominal pain MESHD/cramp, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, restlessness HP, and a higher temperature of >1000F have a greater presentation rate and more frequent than other published studies. CRP and Prothrombin time was found to increase in all the patients. Serum SERO ferritin, ESR, SGPT, and D-Dimer were found increased among 53.85%, 80.43, 44%, and 25% patients respectively. 17.39% of the patients had leukocytosis HP leukocytosis MESHD and neutrophilia HP. 28.26% of patients presented with lymphocytopenia MESHD. 62.52% of patients had mild erythrocytopenia. Conclusion: Despite some similarities, our study has evaluated a different expression in presenting symptoms in the case of COVID-19 patients in Bangladesh. CRP, Prothrombin time, serum SERO ferritin, ESR, SGPT, D-Dimer, erythrocytopenia, and lymphocytopenia MESHD can be initial diagnostic hematological findings and assessment for prognosis COVID-19 disease. Also, gender TRANS variations have a different scenario of clinical and laboratory appearance in this region.

    Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China.

    Authors: Dawei Wang; Yimei Yin; Chang Hu; Xing Liu; Xingguo Zhang; Shuliang Zhou; Mingzhi Jian; Haibo Xu; John Prowle; Bo Hu; Yirong Li; Zhi-Yong Peng

    doi:10.21203/rs.3.rs-16485/v2 Date: 2020-03-04 Source: ResearchSquare

    Background In December 2019, Coronavirus Disease MESHD 2019 (COVID-19) outbreak was reported from Wuhan, China. Information on the clinical course and prognosis of COVID-19 was not thoroughly described. We described the clinical courses and prognosis in COVID-19 patients. Methods Retrospective case series of COVID-19 patients from Zhongnan Hospital of Wuhan University in Wuhan, and Xi-shui Hospital, Hubei Province, China, up to February 10, 2020. Epidemiological, demographic and clinical data were collected. Clinical course of survivors and non-survivors were compared. Risk factors for death MESHD were analyzed. Results A total of 107 discharged patients with COVID-19 were enrolled. The clinical course of COVID-19 presented as a tri-phasic pattern. Week 1 after illness onset was characterized by fever HP fever MESHD, cough HP cough MESHD, dyspnea HP dyspnea MESHD, lymphopenia HP lymphopenia MESHD and radiological multilobar pulmonary infiltrates HP. In severe cases, thrombocytopenia HP thrombocytopenia MESHD, acute kidney injury HP acute kidney injury MESHD, acute myocardial injury MESHD or adult TRANS adult MESHD respiratory distress HP syndrome were observed. During week 2, in mild cases, fever HP fever MESHD, cough HP cough MESHD and systemic symptoms began to resolve and platelet count rose to normal range, but lymphopenia HP lymphopenia MESHD persisted. In severe cases, leukocytosis HP leukocytosis MESHD, neutrophilia HP and deteriorating multi-organ dysfunction were dominant. By week 3, mild cases had clinically resolved except for lymphopenia HP lymphopenia MESHD. However, severe cases showed persistent lymphopenia HP lymphopenia MESHD, severe acute respiratory dyspnea syndrome MESHD dyspnea HP syndrome , refractory shock MESHD shock HP, anuric acute kidney injury MESHD acute kidney injury HP, coagulopathy MESHD, thrombocytopenia HP thrombocytopenia MESHD and death MESHD. Older age TRANS and male TRANS sex were independent risk factors for poor outcome of the illness. Conclusions A period of 7–13 days after illness onset is the critical stage in COVID-19 course. Age TRANS and male TRANS gender TRANS were independent risk factors for death of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.